Long-Term Disease Stabilization in a Patient with Castration-Resistant Metastatic Prostate Cancer by the Addition of Lenalidomide to Low-Dose Dexamethasone and Celecoxib

Publisher： Karger

E-ISSN： 2296-5262|35|5|279-282

ISSN： 2296-5270

Source： Oncology Research and Treatment, Vol.35, Iss.5, 2012-04, pp. : 279-282

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Long-Term PSA Control with Repeated Stereotactic Body Radiotherapy in a Patient with Oligometastatic Castration-Resistant Prostate Cancer

By  

Oncology Research and Treatment, Vol. 39, Iss. 4, 2016-03 ,pp. : 217-220

Karger

Access to resources Recommend Favorite

Phase II trial of docetaxel, bevacizumab, lenalidomide and prednisone in patients with metastatic castration‐resistant prostate cancer

By  

BJU INTERNATIONAL, Vol. 118, Iss. 4, 2016-10 ,pp. : 590-597

John Wiley & Sons Inc

Access to resources Recommend Favorite

Is prostate cancer changing?: Evolving patterns of metastatic castration‐resistant prostate cancer

By  

CANCER, Vol. 120, Iss. 6, 2014-03 ,pp. : 833-839

John Wiley & Sons Inc

Access to resources Recommend Favorite

Cabazitaxel for the therapy of metastatic castration‐resistant prostate cancer in the aftermath of the CHAARTED trial

By  

BJU INTERNATIONAL, Vol. 116, Iss. 6, 2015-12 ,pp. : 839-840

John Wiley & Sons Inc

Access to resources Recommend Favorite

Is angiogenesis still an attractive target in metastatic castration‐resistant prostate cancer?

By  

BJU INTERNATIONAL, Vol. 116, Iss. 4, 2015-10 ,pp. : 500-501

John Wiley & Sons Inc

Access to resources Recommend Favorite